Trade CSPC Pharmaceutical Group Limited - 1093 CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.1
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.01838 %(-HK$3.68)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.01838%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentHK$1,000.00Overnight funding adjustmentCharges from full value of position-0.00354 %(-HK$0.71)Trade size with leverage ~ HK$20,000.00Money from leverage ~ $HK$19,000.00Go to platform: -0.00354%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: HKD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: Hong Kong
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01838 %
  (-HK$3.68)

• Margin. Your investment: HK$1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00354 %
  (-HK$0.71)

Key Stats

• Prev. Close: 8.8
• Open: 8.7
• 1-Year Change: N/A
• Day's Range: 8.65 - 8.9

Trade CSPC Pharmaceutical Group Limited - 1093

About CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CSPC Pharmaceutical Group Ltd revenues increased 12% to RMB27.87B. Net income increased 9% to RMB5.61B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Selling and distribution expenses increase of 11% to RMB10.44B (expense), Research and development expenses increase of 19% to RMB3.43B (expense).